Phio Pharmaceuticals Corp (PHIO) News
Filter PHIO News Items
PHIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PHIO News Highlights
- PHIO's 30 day story count now stands at 3.
- Over the past 28 days, the trend for PHIO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NOV, PH and HA are the most mentioned tickers in articles about PHIO.
Latest PHIO News From Around the Web
Below are the latest news stories about PHIO PHARMACEUTICALS CORP that investors may wish to consider to help them evaluate PHIO as an investment opportunity.
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross ProceedsMARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023, ha |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to dive into the biggest pre-market stock movers for Wednesday with a breakdown of all the latest news this morning! |
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateMARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended September 30, 2023 and provided a business update. “We have enrolled the first patient in our U.S. clinical trial with PH-762,” announced Phio’s President & CEO, Robert Bitterman. “ |
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin CarcinomasMARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that the first patient has been dosed in the Phase 1b clinical trial of PH-762, an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells’ ability to kill cancer cells. This clinical trial is d |
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor ControlIntratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapiesMARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announ |
Dear Ehang (EH) Stock Fans, Mark Your Calendars for Oct. 13Fans of Ehang stock will want to prepare for major movement on Friday as shares of EH will no longer be suspended that day! |
Why Is Phio Pharma (PHIO) Stock Down 35% Today?Phio Pharma stock is pulling back on Thursday after shares of PHIO underwent a massive rally on Wednesday with a preclinical trial update. |
This Costco Insider Just Sold 1,200 Shares of COST StockCostco stock is on the move Thursday as investors in the retail company react to news of insider selling of COST shares. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayPre-market stock movers are a hot topic among traders on Thursday and we're offering all of the latest coverage this morning! |
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug DataData from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer. |